Cargando…

PBPK perspective on alternative CYP3A4 inducers for rifampin

Detalles Bibliográficos
Autores principales:	Chen, Kuan‐Fu, Jones, Hannah M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Perspectives
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755915/ https://www.ncbi.nlm.nih.gov/pubmed/36146978 http://dx.doi.org/10.1002/psp4.12864

Ejemplares similares

Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPK
por: Wagner, C, et al.
Publicado: (2015)

Reproducing prolonged time to peak bisoprolol concentration by PBPK modeling with lysosomal trapping in enterocytes
por: Wu, Dan‐Na, et al.
Publicado: (2022)

Where Do PBPK Models Stand in Pharmacometrics and Systems Pharmacology?
por: Jamei, Masoud
Publicado: (2020)

Controversy about the Role of Rifampin in Biofilm Infections: Is It Justified?
por: Renz, Nora, et al.
Publicado: (2021)

Report from the EMA workshop on qualification and reporting of physiologically based pharmacokinetic (PBPK) modeling and simulation
por: Zhao, P
Publicado: (2017)

An Integrated Approach for Assessing the Impact of Renal Impairment on Pharmacokinetics of Drugs in Development: Pivotal Role of PBPK Modelling
por: Rowland Yeo, Karen, et al.
Publicado: (2021)

PBPK Models for CYP3A4 and P‐gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin
por: Hanke, Nina, et al.
Publicado: (2018)

A PBPK Model to Predict Disposition of CYP3A-Metabolized Drugs in Pregnant Women: Verification and Discerning the Site of CYP3A Induction
por: Ke, A B, et al.
Publicado: (2012)

Tiered approach to evaluate the CYP3A victim and perpetrator drug–drug interaction potential for vonoprazan using PBPK modeling and clinical data to inform labeling
por: Mulford, Darcy J., et al.
Publicado: (2023)

An Alternative Perspective for the Theory of Biological Control
por: Mills, Nicholas J.
Publicado: (2018)

Perspectives on an alternative career path in regulatory science
por: Fields, F. Owen
Publicado: (2013)

Need for alternatives to animals in experimentation: An Indian perspective
por: Swaminathan, Soumya, et al.
Publicado: (2019)

Physiologically Based Pharmacokinetic (PBPK) Modeling of Clopidogrel and Its Four Relevant Metabolites for CYP2B6, CYP2C8, CYP2C19, and CYP3A4 Drug–Drug–Gene Interaction Predictions
por: Loer, Helena Leonie Hanae, et al.
Publicado: (2022)

Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model
por: Kuepfer, L, et al.
Publicado: (2016)

PBPK modeling to predict drug‐drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction
por: Bolleddula, Jayaprakasam, et al.
Publicado: (2021)

Perspective: Therapeutic Potential of Flavonoids as Alternative Medicines in Epilepsy
por: Kwon, Jae Young, et al.
Publicado: (2019)

Approaches to developing alternative and predictive toxicology based on PBPK/PD and QSAR modeling.
por: Yang, R S, et al.
Publicado: (1998)

Development and application of a PBPK modeling strategy to support antimalarial drug development
por: Abla, Nada, et al.
Publicado: (2023)

Utility of endogenous 4β-hydroxycholesterol as a biomarker to assess cytochrome P 450 3A (CYP3A) activity: not quite ready for prime time
por: Tung, Norint P., et al.
Publicado: (2022)

Etymologia: Rifampin
por: Henry, Ronnie
Publicado: (2018)

Physiologically based pharmacokinetic (PBPK) modeling of the role of CYP2D6 polymorphism for metabolic phenotyping with dextromethorphan
por: Grzegorzewski, Jan, et al.
Publicado: (2022)

Pharmacokinetic Evaluation of CYP3A4‐Mediated Drug‐Drug Interactions of Isavuconazole With Rifampin, Ketoconazole, Midazolam, and Ethinyl Estradiol/Norethindrone in Healthy Adults
por: Townsend, Robert, et al.
Publicado: (2016)

Deranged Haemostasis: Rifampin-Induced Coagulopathy
por: Tiperneni, Raghu, et al.
Publicado: (2022)

The pharmacokinetics of pamiparib in the presence of a strong CYP3A inhibitor (itraconazole) and strong CYP3A inducer (rifampin) in patients with solid tumors: an open-label, parallel-group phase 1 study
por: Mu, Song, et al.
Publicado: (2021)

Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models
por: Vossen, Michaela, et al.
Publicado: (2007)

Perspective: Multiomics and Machine Learning Help Unleash the Alternative Food Potential of Microalgae
por: Helmy, Mohamed, et al.
Publicado: (2022)

Non-canonical alternatives: What a macrophage is 4
por: Karp, Christopher L., et al.
Publicado: (2012)

CYP2C8 and antimalaria drug efficacy
por: Gil, JP, et al.
Publicado: (2007)

Relevance and therapeutic potential of CypA targeting to block apoptosis inducing factor-mediated neuronal cell death
por: Doti, Nunzianna, et al.
Publicado: (2017)

Complementary and alternative medicine use among diabetic patients in Africa: a Kenyan perspective
por: Matheka, Duncan Mwangangi, et al.
Publicado: (2013)

FRI215 Rifampin Induced Adrenal Insufficiency
por: Campbell, Spencer Ramon, et al.
Publicado: (2023)

Alternative Perspectives on Impact: The Potential of ALMs and Altmetrics to Inform Funders about Research Impact
por: Dinsmore, Adam, et al.
Publicado: (2014)

Novel Bruton’s Tyrosine Kinase inhibitor remibrutinib: Drug‐drug interaction potential as a victim of CYP3A4 inhibitors based on clinical data and PBPK modeling
por: Huth, Felix, et al.
Publicado: (2021)

Perspectives on Using Physcomitrella Patens as an Alternative Production Platform for Thapsigargin and Other Terpenoid Drug Candidates
por: Simonsen, Henrik Toft, et al.
Publicado: (2009)

Rifampin-induced Pseudomembranous Colitis with Rectosigmoid Sparing
por: Yim, Sun Young, et al.
Publicado: (2011)

Clarithromycin–Rifampin-Based Treatment for Nontuberculous Mycobacteria Infections in Immunocompromised Patients who Require Concomitant CYP-Metabolized Medications
por: Gonzalez-Bocco, Isabel H, et al.
Publicado: (2021)

PBPK modeling of ivermectin—Considerations for the purpose of developing alternative routes to optimize its safety profile
por: Rowland Yeo, Karen, et al.
Publicado: (2023)

Towards a Best Practice Approach in PBPK Modeling: Case Example of Developing a Unified Efavirenz Model Accounting for Induction of CYPs 3A4 and 2B6
por: Ke, A, et al.
Publicado: (2016)

Impact of Disease on Plasma and Lung Exposure of Chloroquine, Hydroxychloroquine and Azithromycin: Application of PBPK Modeling
por: Rowland Yeo, Karen, et al.
Publicado: (2020)

Gynecological cancers: an alternative approach to healing
por: Saso, Srdjan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_r90o9aqesdfu8v3t7hupk34af5